Literature DB >> 20406789

Significant fall in hormone replacement therapy prescription in general practice.

Alm Lagro-Janssen1, M W A Knufing, L Schreurs, C van Weel.   

Abstract

BACKGROUND: Hormone replacement therapy (HRT) in the past has been used in one of five women but not without significant short-term and long-term consequences. Objective. The aim of the study is to assess the prescription of HRT in general practice to women consulting with menopausal symptoms, before and after publication of the Women's Health Initiative (WHI) study (2002), the Million Women Study and the Lancet Editorial (2003), and to correlate these with co-morbidity, co-medication and frequency of GP consultation. Methods. The study was performed using data collected by a Dutch Continuous Morbidity Registration. We selected women who presented with menopausal symptoms for the first time during the period 1999-2007 (n=341). Women who were prescribed HRT between 2002 and 2007 were compared with women presenting with menopausal symptoms without HRT prescription and women who did not consult for menopausal symptoms. Both control groups were matched for age, socio-economic status and general practice. Results. HRT prescription decreased considerably: from 37% in all women who present with menopausal symptoms at the GP 2002 to 14% in 2003 and 4% in 2004. Women who consulted for menopausal symptoms, irrespective of HRT prescription, presented with nervous functional complaints more often, were prescribed more tranquillizers and visited the GP more frequently than women who did not consult for menopausal symptoms. Conclusions. These GPs were very quick to implement new recommendations on HRT prescription. The decision to prescribe HRT was not correlated with specific emotional or psychiatric problems of the menopausal women.

Entities:  

Mesh:

Year:  2010        PMID: 20406789     DOI: 10.1093/fampra/cmq018

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  6 in total

1.  Effects of soy phytoestrogens on pituitary-ovarian function in middle-aged female rats.

Authors:  Ivana M Medigović; Jasmina B Živanović; Vladimir Z Ajdžanović; Aleksandra L Nikolić-Kokić; Sanja D Stanković; Svetlana L Trifunović; Verica Lj Milošević; Nataša M Nestorović
Journal:  Endocrine       Date:  2015-07-28       Impact factor: 3.633

Review 2.  Menopausal hormone therapy and breast cancer mortality: clinical implications.

Authors:  Rowan T Chlebowski; Garnet L Anderson
Journal:  Ther Adv Drug Saf       Date:  2015-04

3.  Role of inducible nitric oxide synthase in endothelium-independent relaxation to raloxifene in rat aorta.

Authors:  Chi Ming Wong; Chak Leung Au; Suk Ying Tsang; Chi Wai Lau; Xiaoqiang Yao; Zongwei Cai; Arthur Chi-Kong Chung
Journal:  Br J Pharmacol       Date:  2017-02-27       Impact factor: 8.739

4.  Tetragonia tetragonioides (Pall.) Kuntze protects estrogen-deficient rats against disturbances of energy and glucose metabolism and decreases proinflammatory cytokines.

Authors:  Jin Ah Ryuk; Byoung-Seob Ko; Hye Won Lee; Da Sol Kim; Suna Kang; Yong Hyen Lee; Sunmin Park
Journal:  Exp Biol Med (Maywood)       Date:  2016-12-13

5.  The proportion of postmenopausal breast cancer cases in the Netherlands attributable to lifestyle-related risk factors.

Authors:  W A van Gemert; C I Lanting; R A Goldbohm; P A van den Brandt; H G Grooters; E Kampman; L A L M Kiemeney; F E van Leeuwen; E M Monninkhof; E de Vries; P H Peeters; S G Elias
Journal:  Breast Cancer Res Treat       Date:  2015-06-05       Impact factor: 4.872

6.  Rationale and design of a cohort study on primary ovarian insufficiency in female survivors of Hodgkin's lymphoma: influence on long-term adverse effects (SOPHIA).

Authors:  Inge M Krul; Annemieke W J Opstal-van Winden; Josée M Zijlstra; Yolande Appelman; Sanne B Schagen; Lilian J Meijboom; Erik Serné; Cornelis B Lambalk; Paul Lips; Eline van Dulmen-den Broeder; Michael Hauptmann; Laurien A Daniëls; Berthe M P Aleman; Flora E van Leeuwen
Journal:  BMJ Open       Date:  2018-09-11       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.